Shalby Limited — Investor Meet, 18-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Shalby's Q3 FY26 consolidated revenue saw a marginal dip YoY to INR 279.4 Cr, with EBITDA at INR 37.5 Cr (13.4% margin). PAT improved to INR 1.3 Cr from a negative last year. The hospital business faced Q3 headwinds from insurance renegotiations (now resolved) and doctor exits, impacting standalone revenue and EBITDA. Management highlights new doctor recruitment and investments in robotics and diagnostics to drive future growth. The MedTech arm reported strong 29% YoY revenue growth to INR 30.38 Cr, turning EBITDA positive at INR 0.07 Cr, reflecting improved cost efficiency. Management anticipates double-digit volume growth and 5-6% ARPOB growth in the hospital segment, with MedTech's capacity issues largely resolved.